Rotational stability and clinical outcomes of a new one piece toric intraocular lens with anchor-wing haptics

BMC Ophthalmology

Kazuo Ichikawa¹  Kazuno Negishi²  Tomoichiro Ogawa³  Tadashi Nakano³  Hiroshi Tsuneoka³  Iichiro Sugita⁴  Takahide Okita⁴ 

[1] Chukyo Eye Clinic;Department of Ophthalmology, Keio University School of Medicine;Department of Ophthalmology, the Jikei University School of Medicine;Sugita Eye Hospital;

关键词: Toric intraocular lens;    Intraocular lens;    Corneal astigmatism;    Cataract;    Cataract surgery;    Rotational stability;   

DOI  :  10.1186/s12886-021-02240-7

来源: DOAJ

【 摘 要 】

Abstract Background To evaluate the safety and efficacy of a new toric intraocular lens (IOL) with anchor-wing haptics. Methods The new toric IOL with anchor-wing haptics (NS60YT, NIDEK Co., Ltd.) was implanted in eligible patients with age-related cataracts with preoperative corneal astigmatism of 1.0 D or greater at a university hospital and two private hospitals in Japan. The following IOL cylinder powers were evaluated: 1.50 D (NS60YT3), 2.25 D (NS60YT4), 3.00 D (NS60YT5) and 4.50 D (NS60YT7). All patients were assessed out to 12 months postoperatively. The primary endpoint was visual acuity (VA) with spherical addition at 6 months postoperatively, and the primary analysis calculated the proportion of eyes with VA with spherical addition of 0.1 logMAR or better. The magnitude of rotation was compared to the intended axis of IOL implantation at each postoperative examination. Adverse events were evaluated for the safety analysis. Results This study enrolled 64 eyes of 53 patients. At 6 months postoperatively, for all IOL powers, VA with spherical addition of 0.1 logMAR or better was achieved in 90% [95% confidence interval (CI): 80–96] of eyes. The mean IOL rotation was 5.3 ± 4.3° at 12 months postoperatively. The mean magnitude of rotation ranged from 1.9° to 2.5° between each postoperative examination from 1 day to 12 months. There were no vision-threatening intraoperative or postoperative complications for the duration of the study. Conclusions The NS60YT IOL remained stable after implantation and was efficacious for treating 1.00 D or greater astigmatism in patients with senile cataracts. Trial registration This study was registered at ClinicalTrials.gov ( NCT03242486 ) on August 8, 2017 - Retrospectively registered.

【 授权许可】

Unknown